Ferric derisomaltose

From Wikipedia, the free encyclopedia

Ferric derisomaltose
Clinical data
Trade namesMonoferric
License data
Routes of
Intravenous (IV)
ATC code
  • None
Legal status
Legal status
  • iron(3+);(2S,3R,4R,5R)-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexane-1,2,3,4,5-pentol
CAS Number
PubChem CID
Chemical and physical data
Molar mass562.299 g·mol−1
3D model (JSmol)
  • C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)OCC(C(C(C(CO)O)O)O)O)O)O)O)O)O)O)O.[Fe+3]
  • InChI=1S/C18H34O16.Fe/c19-1-5(21)9(23)10(24)6(22)3-31-17-16(30)14(28)12(26)8(34-17)4-32-18-15(29)13(27)11(25)7(2-20)33-18;/h5-30H,1-4H2;/q;+3/t5-,6+,7+,8+,9+,10+,11+,12+,13-,14-,15+,16+,17-,18-;/m0./s1

Ferric derisomaltose, sold under the brand name Monoferric, is a medication for the treatment of iron deficiency anemia (IDA) in adults who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease (NDD-CKD).[2] It was approved for use in the United States in January 2020.[2][3][4] It is given intravenously.[2]


  1. ^ "Search Page - Drug and Health Product Register". 23 October 2014.
  2. ^ a b c d "Monoferric- ferric derisomaltose solution". DailyMed. 24 January 2020. Retrieved 16 February 2020.
  3. ^ "Monoferric approval letter" (PDF). U.S. Food and Drug Administration (FDA). 16 January 2020. Retrieved 16 February 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ "Drug Approval Package: Monoferric Injection". U.S. Food and Drug Administration (FDA). 7 May 2020. Retrieved 13 August 2020.

External links[edit]